scholarly journals Preventive Effect of Dietary Fermented Soybean on Bone Loss in Ovariectomized Rats. Enhancement with Isoflavone and Zinc Supplementation.

2000 ◽  
Vol 46 (4) ◽  
pp. 263-268 ◽  
Author(s):  
Zhong Jie Ma ◽  
Shigefumi Shimanuki ◽  
Aki Igarashi ◽  
Yoshiyuki Kawasaki ◽  
Masayoshi Yamaguchi
Keyword(s):  
Bone Loss ◽  
Zinc Supplementation ◽  
Ovariectomized Rats ◽  
Preventive Effect ◽  
Fermented Soybean

Prolonged intake of fermented soybean ( natto ) diets containing vitamin K 2 (menaquinone-7) prevents bone loss in ovariectomized rats

2000 ◽  
Vol 18 (2) ◽  
pp. 71-76 ◽  
Author(s):  
Masayoshi Yamaguchi ◽  
Hiroyuki Kakuda ◽  
Ying Hua Gao ◽  
Yoshinori Tsukamoto
Keyword(s):  
Bone Loss ◽  
Vitamin K ◽  
Ovariectomized Rats ◽  
Fermented Soybean

scholarly journals Evaluation of the Preventive Effect of Isoflavone Extract on Bone Loss in Ovariectomized Rats

2004 ◽  
Vol 68 (5) ◽  
pp. 1040-1045 ◽  
Author(s):  
Yoon-Bok LEE ◽  
Hyong Joo LEE ◽  
Kang Sung KIM ◽  
Jae-Yong LEE ◽  
Sang-Yoon NAM ◽  
...  
Keyword(s):  
Bone Loss ◽  
Ovariectomized Rats ◽  
Preventive Effect

Effect of vitamin K 2 (menaquinone-7) in fermented soybean ( natto ) on bone loss in ovariectomized rats

1999 ◽  
Vol 17 (1) ◽  
pp. 23-29 ◽  
Author(s):  
Masayoshi Yamaguchi ◽  
Hideaki Taguchi ◽  
Ying Hua Gao ◽  
Aki Igarashi ◽  
Yoshinori Tsukamoto
Keyword(s):  
Bone Loss ◽  
Vitamin K ◽  
Ovariectomized Rats ◽  
Fermented Soybean

The preventive effect on bone loss of 50-Hz, 1-mT electromagnetic field in ovariectomized rats

2002 ◽  
Vol 20 (6) ◽  
pp. 345-349 ◽  
Author(s):  
Cemil Sert ◽  
Mustafa Denz ◽  
M. Zahir Düz ◽  
Feyzan Akşen ◽  
Abdurrahman Kaya
Keyword(s):  
Electromagnetic Field ◽  
Bone Loss ◽  
Ovariectomized Rats ◽  
Preventive Effect

scholarly journals Combination treatment with pioglitazone and fenofibrate attenuates pioglitazone-mediated acceleration of bone loss in ovariectomized rats

2011 ◽  
Vol 212 (2) ◽  
pp. 179-186 ◽  
Author(s):  
Rana Samadfam ◽  
Malaika Awori ◽  
Agnes Bénardeau ◽  
Frieder Bauss ◽  
Elena Sebokova ◽  
...  
Keyword(s):  
Bone Loss ◽  
Bone Mass ◽  
Trabecular Bone ◽  
Bone Mineral ◽  
Combination Treatment ◽  
Mass Gain ◽  
Ovariectomized Rats ◽  
Concomitant Treatment ◽  
Mineral Density ◽  
Ovx Rats

Peroxisome proliferator-activated receptor (PPAR) γ agonists, such as pioglitazone (Pio), improve glycemia and lipid profile but are associated with bone loss and fracture risk. Data regarding bone effects of PPARα agonists (including fenofibrate (Feno)) are limited, although animal studies suggest that Feno may increase bone mass. This study investigated the effects of a 13-week oral combination treatment with Pio (10 mg/kg per day)+Feno (25 mg/kg per day) on body composition and bone mass parameters compared with Pio or Feno alone in adult ovariectomized (OVX) rats, with a 4-week bone depletion period, followed by a 6-week treatment-free period. Treatment of OVX rats with Pio+Feno resulted in ∼50% lower fat mass gain compared with Pio treatment alone. Combination treatment with Pio+Feno partially prevented Pio-induced loss of bone mineral content (∼45%) and bone mineral density (BMD; ∼60%) at the lumbar spine. Similar effects of treatments were observed at the femur, most notably at sites rich in trabecular bone. At the proximal tibial metaphysis, concomitant treatment with Pio+Feno prevented Pio exacerbation of ovariectomy-induced loss of trabecular bone, resulting in BMD values in the Pio+Feno group comparable to OVX controls. Discontinuation of Pio or Feno treatment of OVX rats was associated with partial reversal of effects on bone loss or bone mass gain, respectively, while values in the Pio+Feno group remained comparable to OVX controls. These data suggest that concurrent/dual agonism of PPARγ and PPARα may reduce the negative effects of PPARγ agonism on bone mass.

Sign in / Sign up

Export Citation Format

Share Document